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Letter to the Editor
Protracted Neutropenia After
Treatment With
Non-Clozapine Antipsychotic
Medications
To the Editors:
mong antipsychotic medications, clozapine is known for inducing neutropenia, defined as an absolute neutrophil
count (ANC) <1500/μL. Yet, studies suggest that a variety of non-clozapine antipsychotic medications are also implicated in
the development of neutropenia.1,2 Specifically, a meta-analysis concluded that there
were no statistically significant differences
in the incidences of neutropenia secondary
to clozapine compared with incidences of neutropenia secondary to non-clozapine antipsychotic medications.3 Although the United
States Risk Evaluation and Mitigation Strate-
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gies stipulate specific ANC monitoring guidelines and parameters for clozapine because of
risk of neutropenia and agranulocytosis, there
are no established ANC monitoring guidelines
for non-clozapine antipsychotic medications.
Although neutropenia may be asymptomatic, it can result in recurrent infections,
fever, and sepsis. Moreover, although drugassociated neutropenia is typically transient,
a patient may develop recurrent neutropenia
in the future with another medication.4–8
Hence, awareness of ANC is clinically relevant, even when using non-clozapine antipsychotic medications. To our knowledge,
there are no reported cases of non-clozapine
antipsychotic medication-associated neutropenia lasting for longer than 1 month. Herein,
we present the case of a woman who developed a protracted course of neutropenia
after treatment with 3 non-clozapine antipsychotic medications, which ultimately resolved with antipsychotic medication cessation and lithium treatment. Written consent
to publish a report of the case was obtained. Information was deidentified to
protect anonymity.

CASE REPORT
A 28-year-old White woman with nonHashimoto hypothyroidism and no personal
or family history of blood dyscrasias presented to our psychiatric clinic with dysphoric mood. She was taking levothyroxine
50 μg daily and reported not using other
medications or substances. At the time, her
presentation appeared consistent with bipolar II disorder. She was sequentially prescribed aripiprazole 15 mg daily and
cariprazine 3 mg daily, which were discontinued after 1 and 2 months, respectively, because of lack of efficacy. Lurasidone was subsequently initiated and titrated to 40 mg daily;
propranolol 10 mg twice daily was added
for akathisia.
A baseline complete blood count with
differential (CBC with diff ), glycolated hemoglobin, and lipid profile were ordered before antipsychotic medication initiation.
However, laboratory procedures were not
completed until 6 months into lurasidone
treatment. Absolute neutrophil count was
found to be 1200/μL, decreased from
3800/μL as measured before any antipsychotic medication treatment. Her physical
examination was unremarkable. With this
decrement in ANC, as well as intolerable
side effects, lurasidone and propranolol were
tapered off; and her internist referred her to
hematology/oncology and rheumatology
for further evaluation.
A comprehensive workup revealed a positive antinuclear antibody (ANA) titer (1:1280).
Rheumatoid factor, anti–scleroderma-70, antiRo, anti-La, anti-smith, ribonucleotide peptide,
complements C3 and C4, double-stranded

DNA, antihistone, cyclic citrullinated peptide,
hepatitis B and C antibodies, and human immunodeficiency virus-1 p24-antigen resulted
negative. Urinalysis, monoclonal protein
evaluation, vitamin B12, folate, erythrocyte
sedimentation rate, C-reactive protein, creatinine phosphokinase, and thyroid-stimulating
hormone were all normal.
After lurasidone discontinuation, the
patient's ANC remained low and fluctuated
between 700 and 1400/μL over 12 weeks.
Although no fevers were noted, she periodically endorsed fatigue. There were no
changes made to her levothyroxine dose,
and there were no other nonpsychotropic
medications initiated during this time. Specialists suspected that her neutropenia was
secondary to lurasidone treatment. She was
started on 600-mg lithium-controlled release
nightly. Serum lithium level and renal and
thyroid function were monitored accordingly. After 6 months, her ANC normalized
to 2400 to 2900/μL.

DISCUSSION
Neutropenia can be characterized as mild
(ANC, 1000–1400/μL), moderate (ANC,
500–999/μL), or severe (ANC, less than
500/μL). Among other causes, the origin of
neutropenia may be congenital, related to
mutations affecting myeloid gene precursors.
It may also occur secondary to medications,
benign ethnic neutropenia, which typically
affects individuals of African, Middle Eastern, and West Indian lineage, malignancies
affecting bone marrow reserve, nutrient deficiencies, infections, autoimmune disorders,
or hypothyroidism.9–11 Of note, clozapineinduced neutropenia is associated with HLADBQ1 variants in individuals of European
ancestry.12 Although we did not pursue genetic or biochemical analysis for our patient, the Naranjo scores for aripiprazole
(3), cariprazine (2), and lurasidone (3) suggest
possible drug-associated neutropenia.13
While a literature search reveals no reports of cariprazine-associated neutropenia,
neutropenia secondary to aripiprazole and
lurasidone treatment has been reported.6,8,14–16
Most cases of drug-associated neutropenia
resolve within 1 month of medication cessation alone.2,17 While our patient's ANC may
have increased after cessation of the
lurasidone alone, given that she still had
neutropenia 12 weeks after its cessation, we decided to initiate lithium. Lithium, which is classically used off-label for clozapine-associated
neutropenia, modulates neutrophil count by
promoting granulocyte colony stimulating
factor production and pluripotent stem cell
proliferation.18 Though not extensively reported, lithium may be useful for nonclozapine antipsychotic drug-associated neutropenia which persists after the suspected

© 2022 Wolters Kluwer Health, Inc. All rights reserved.

Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

Journal of Clinical Psychopharmacology • Volume 42, Number 6, November/December 2022

offending agent has been discontinued, as may
have been demonstrated in our case.
There are limitations that should be
considered. As she was trialed on aripiprazole and cariprazine before lurasidone,
ANC was not checked while she was on
these medications, and there was not a
washout period without antipsychotic medications, neutropenia may have been associated and potentiated by any of these medications. In addition, given that our patient
had an elevated ANA titer, it is possible that
an autoimmune disorder may have contributed to the development of neutropenia. Yet,
ANA is not a specific measure of autoimmunity, and since the comprehensive autoimmune panel was otherwise unremarkable, this
explanation is less likely. Drug-associated
lupus, potentially secondary to propranolol, may also have resulted in both elevated
ANA titer and neutropenia. However, the
lack of antihistone antibodies points away
from this possibility. Moreover, other infections may have contributed to her neutropenia; however, this is unlikely given the
lack of C-reactive protein elevations or fever.
Finally, White patients may have benign
decrements in ANC for no apparent reason,
although this is relatively less common.19
Overall, as seen in our patient, ANC
can fluctuate in individuals prescribed
non-clozapine antipsychotic medications,
even in the absence of benign ethnic neutropenia, concomitant use of neutropenia-associated
medications, or known blood dyscrasias.
Although our patient had mild to moderate
neutropenia and her antipsychotic medications were discontinued because of lack of
efficacy or tolerability, had her ANC not
been checked, continued antipsychotic
medication use may have potentially resulted in persistent neutropenia or progressed to agranulocytosis. We therefore
propose that baseline and routine CBC
with diff monitoring in patients who are
prescribed any antipsychotic medication is
a worthy intervention. Because CBC is already ordered as part of the standard
workup of first-episode psychosis and depressive disorders, and glycolated hemoglobin and lipid profiles are monitored at
least once yearly in patients prescribed antipsychotic medications, baseline and routine monitoring of CBC with diff can practically be completed without concerns for
any additional burden for compliance on
the patient. As per Risk Evaluation and
Mitigation Strategies, when prescribing
clozapine, a decrease in ANC to the mild
or moderate range is not necessarily a reason
to discontinue it indefinitely. Similarly, we argue that decreases in ANC to the mild to
moderate range of patients prescribed nonclozapine antipsychotic medications should
not necessarily prohibit their use or be a

reason to withhold treatment. Rather, routine monitoring may offer a chance for physicians to intervene and involve appropriate
specialty services to elucidate reasons for
neutropenia to help guide future treatment
as deemed clinically necessary.
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To the Editors:
lbuterol (Teva Pharmaceuticals, Horsham,
PA) is typically considered a relatively
benign medication free from major drug interactions and serious side effects, which
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